Meeting
2022 ASCO Annual Meeting
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
Authors
Brittany K. Ragon
Levine Cancer Institute, Atrium Health, Charlotte, NC
Brittany K. Ragon , Anita D'Souza , Noel Estrada-Merly , Raphael Fraser , Gemlyn George , Lohith Gowda , Nina Shah , Muzaffar H. Qazilbash , Shaji Kumar , Mary M. Horowitz , Saad Zafar Usmani , Mithun Vinod Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8057)
DOI
10.1200/JCO.2022.40.16_suppl.8057
Abstract #
8057
Poster Bd #
480
Abstract Disclosures
Similar Posters
First Author: George Somlo
Poster
2015 ASCO Annual Meeting
Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).
First Author: Sarah A. Holstein
Poster
2023 ASCO Annual Meeting
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.
First Author: Samer Al Hadidi
Poster
2021 ASCO Annual Meeting
Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study.
First Author: Oren Pasvolsky